Asahi Intecc (7747) investor relations material

Vision and strategic direction

• Aims to become a global niche-leading company offering comprehensive solutions for minimally invasive treatment, contributing to longer, healthier lives.

• Focuses on sustainable growth by addressing clinical needs with unique technologies and high value-added products.

• Maintains a hands-on approach, leveraging four core technologies and an integrated production system.

• Pursues innovation through R&D, expanding both cardiovascular and non-cardiovascular product lines.

• Emphasizes global market presence, supplying products to 121 countries and regions.

Financial targets and performance

• Revised upward the medium-term management plan targets: net sales of 212.5 billion yen and operating profit of 68.0 billion yen by FYE June 2030.

• Long-term vision targets net sales of 330.0 billion yen and an operating profit margin of 33%.

• Gross profit margin expected to reach 72.5% and ROE to 20% by FYE June 2030.

• Capital allocation balances growth investments, R&D, shareholder returns, and M&A, with a five-year operating cash flow of 335.0 billion yen.

• Weighted average cost of capital (WACC) projected to rise to 7.4% by FYE June 2026.

Growth strategies and business portfolio

• Plans to accelerate growth by expanding high value-added treatment devices and entering new business areas, including companion animal medical devices.

• Strengthens global sales, especially in the U.S., Europe, China, and Japan, through direct sales and distributor networks.

• Pursues M&A and alliances to enhance product offerings and market reach.

• Invests in R&D and production systems optimized for global expansion, including new factories and automation.

• Develops next-generation smart medical devices and software as a medical device (SaMD).